Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002358 · ClinicalTrials.gov registry record · Phase 3
A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002358: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00002358 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002358, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.
Interventions
- DRUG Sorivudine
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00002358 record still lists
NCT00002358 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Sorivudine is the first listed.
NCT00002358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002358 about?
NCT00002358 is a clinical study titled "A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV". To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.
What is the current status of trial NCT00002358?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002358?
The interventions under investigation include: Sorivudine (DRUG).
Who is sponsoring clinical trial NCT00002358?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.